Mittwoch, 28. Juli 2021
Navigation öffnen
Anzeige:
Canakinumab
Canakinumab
 
JOURNAL ONKOLOGIE – STUDIE
FLASH

Efficacy and Safety of L19TNF in Previously Treated Patients With Advanced Stage or Metastatic Soft-tissue Sarcoma

Rekrutierend

NCT-Nummer:
NCT04733183

Studienbeginn:
August 2020

Letztes Update:
01.02.2021

Wirkstoff:
Dacarbazine, Onfekafusp alfa

Indikation (Clinical Trials):
Sarcoma

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
Phase 2

Sponsor:
Philogen S.p.A.

Collaborator:
-

Kontakt

Studienlocations
(1 von 1)

Münster University Hospital
48149 Münster
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Christoph Schliemann, MD
Phone: +49 251 8346239
E-Mail: Christoph.Schliemann@ukmuenster.de
» Ansprechpartner anzeigen

Studien-Informationen

Detailed Description:

Open label, randomized, controlled phase II study preceded by a safety run-in part in

subjects with advanced or metastatic soft-tissue sarcoma.

- Safety Run-in Part: Six (6) patients will be treated with 1000 mg/m2 dacarbazine (DTIC)

on Day 1 every 3 weeks plus 13 µg/kg L19TNF on Days 1, 3 and 5 every 3 weeks to test for

safety of the combination. Should unacceptable toxicities occur in ≥ 2 patients during

an observation period from Day 1 to Day 21 (first cycle), enrollment will be stopped at

this dose level and 6 patients will be treated sequentially with DTIC at 850 mg/m2 on

Day 1 every 3 weeks plus 13 µg/kg L19TNF on Days 1, 3 and 5 every 3 weeks.

- Tumor Activity Evaluation Part

Approximately 86 patients will be enrolled and parallel assigned in a 1:1 fashion to one of

two different arms, as follows:

- Arm 1: Patients will receive DTIC on Day 1 every 3 weeks plus L19TNF on Days 1, 3 and 5

every 3 weeks.

- Arm 2: Patients will receive DTIC on Day 1 every 3 weeks. During the conduct of the

study, detailed safety parameters will be routinely reviewed by the DSMB.

Ein-/Ausschlusskriterien

Inclusion Criteria:

1. Male or female, 18 to 80 years of age.

2. Histologically or cytologically confirmed advanced unresectable or metastatic soft

tissue sarcoma (STS), Grade 2 - 3 according to the FNLCC grading system. Participants

with bone sarcomas including Ewing sarcoma, Kaposi's sarcoma and gastrointestinal

stromal tumors (GIST) will be excluded.

3. Subjects who received at least two prior systemic therapies (e.g., anthracyclines,

taxanes, ifosfamide, gemcitabine, trabectedin, pazopanib, eribulin) for advanced or

metastatic disease including at least one prior therapy based on anthracyclines as

monotherapy or in combination. Neoadjuvant and adjuvant therapies can be considered as

a prior line of treatment if the time to recurrence from completion of treatment was ≤

12 months. Previous therapy with anthracyclines is not compulsory in situations of

contraindications to this class of drugs. All previous therapies must have completed ≥

3 weeks (21 days) prior to study treatment start.

4. Evidence of disease progression after prior line of therapy for advanced or metastatic

disease.

5. Patients must have at least one unidimensionally measurable lesion by computed

tomography as defined by RECIST criteria v.1.1. If only one lesion is present at

screening this lesion should not have been irradiated during previous treatments.

6. Life expectancy of at least 3 months in the judgment of the investigator.

7. ECOG ≤ 2.

8. Documented negative test for HIV-HBV-HCV. For HBV serology: the determination of

HBsAg, anti-HBsAg-Ab and anti-HBcAg-Ab is required. In patients with serology

documenting previous exposure to HBV (i.e., anti-HBs Ab with no history of vaccination

and/or anti-HBc Ab), negative serum HBV-DNA is required. For HCV: HCV-RNA or HCV

antibody test. Subjects with a positive test for HCV antibody but no detection of

HCV-RNA indicating no current infection are eligible.

9. Female patients: negative serum pregnancy test at screening for women of childbearing

potential (WOCBP)*. WOCBP must agree to use, from the screening to six months

following the last study drug administration, highly effective contraception methods,

as defined by the "Recommendations for contraception and pregnancy testing in clinical

trials" issued by the Head of Medicine Agencies' Clinical Trial Facilitation Group

(www.hma.eu/ctfg.html) and which include, for instance, progesterone-only or combined

(estrogen- and progesterone-containing) hormonal contraception associated with

inhibition of ovulation, intrauterine devices, intrauterine hormone-releasing systems,

bilateral tubal occlusion, vasectomized partner or sexual abstinence. Male patients:

Male subjects able to father children must agree to use two acceptable methods of

contraception throughout the study (e.g. condom with spermicidal gel). Double-barrier

contraception is required.

10. Evidence of a personally signed and dated informed consent document indicating that

the subject has been informed of all pertinent aspects of the study.

11. Willingness and ability to comply with the scheduled visits, treatment plan,

laboratory tests and other study procedures.

- Women of childbearing potential are defined as females who have experienced

menarche, are not postmenopausal (12 months with no menses without an alternative

medical cause) and are not permanently sterilized (e.g., tubal occlusion,

hysterectomy, bilateral oophorectomy or bilateral salpingectomy).

Exclusion Criteria:

1. Anti-cancer treatment with radiation therapy (with the exception of radiation of

single lesions for palliative reasons, e.g. pain management which then are not taken

as indicator lesions for iRECIST response), chemotherapy, targeted therapies,

immunotherapy, hormones or other antitumor therapies within 3 weeks prior to study

treatment start.

2. Subjects who participated in an investigational drug or device study within 3 weeks

prior to study treatment start.

3. Previous treatment with TNF or L19TNF or DTIC.

4. Known history of allergy to intravenously administered human

proteins/peptides/antibodies and any other constituent of the product.

5. Absolute neutrophil count (ANC) < 1.5 x 109/L, platelets < 100 x 109/L and hemoglobin

(Hb) < 9.0 g/dl, with the exception of values lower than these due to cytologically or

histologically proven marrow metastasis, which will not constitute exclusion criteria.

6. Chronically impaired renal function as expressed by creatinine clearance < 60 mL/min

or serum creatinine > 1.5 ULN.

7. Inadequate liver function (ALT or AST ≥ 3 x ULN or ALP or GGT ≥ 2.5 x ULN, or total

bilirubin ≥ 1.5 x ULN). For patients with metastatic lesions in the liver ALT, AST,

GGT or ALP ≥ 5 x ULN.

8. Any severe concomitant condition which in the opinion of investigators makes it

undesirable for the patient to participate in the study or which could jeopardize

compliance with the protocol.

9. History within the last year of cerebrovascular disease and/or acute or subacute

coronary syndromes including myocardial infarction, unstable or severe stable angina

pectoris.

10. Heart insufficiency (> Grade II, New York Heart Association (NYHA) criteria).

11. Clinically significant cardiac arrhythmias.

12. Abnormalities observed during baseline ECG and echocardiogram investigations that are

considered as clinically significant by the investigator.

13. Uncontrolled hypertension.

14. Ischemic peripheral vascular disease (Grade IIb-IV according to Leriche-Fontaine

classification).

15. Severe diabetic retinopathy such as severe non-proliferative retinopathy and

proliferative retinopathy.

16. Major trauma including major surgery (such as abdominal/cardiac/thoracic surgery)

within 4 weeks of administration of study treatment.

17. Pregnancy or breast-feeding.

18. Requirement of chronic administration of corticosteroids or other immunosuppressant

drugs. Limited use of corticosteroids to treat or prevent acute hypersensitivity

reactions is not considered an exclusion criterion.

19. Presence of active and uncontrolled infections or other severe concurrent disease,

which, in the opinion of the investigator, would place the patient at undue risk or

interfere with the study.

20. Known active or latent tuberculosis (TB).

21. Concurrent malignancies other than soft-tissue sarcoma, unless the patient has been

disease-free for at least 2 years.

22. Serious, non-healing wound, ulcer or bone fracture.

23. Allergy to study medication or excipients in study medication.

24. Concurrent therapy with anticoagulants at full therapeutic dose.

25. Concurrent use of other anti-cancer treatments or agents other than study medication.

Studien-Rationale

Primary outcome:

1. Progression-free survival (PFS) (Time Frame - The PFS rate will be assessed at 3 months.):
Progression-free survival (PFS) in according to RECIST v.1.1. The duration is defined beginning from randomization to progression or death from any cause.

2. Progression-free survival (PFS) (Time Frame - The PFS rate will be assessed at 6 months.):
Progression-free survival (PFS) in according to RECIST v.1.1. The duration is defined beginning from randomization to progression or death from any cause.

3. Progression-free survival (PFS) (Time Frame - The PFS rate will be assessed at 9 months.):
Progression-free survival (PFS) in according to RECIST v.1.1. The duration is defined beginning from randomization to progression or death from any cause.

4. Progression-free survival (PFS) (Time Frame - The PFS rate will be assessed at 12 months.):
Progression-free survival (PFS) in according to RECIST v.1.1. The duration is defined beginning from randomization to progression or death from any cause.

Secondary outcome:

1. Overall Survival (OS) (Time Frame - The OS will be calculated at 12, 18, 24 and 36 months.):
Overall Survival (OS) will be assessed for all randomized patients. The duration is defined beginning from randomization to death from any cause.

2. Objective response rate (ORR) (Time Frame - The ORR rate will be assessed at 3, 6, 9, 12 months.):
Objective response rate (ORR, consisting of CR plus PR; only the non-irradiated lesions are measured) according to RECIST v.1.1 between arms.

3. Objective Response Rate (ORR) (Time Frame - The ORR rate will be assessed at 3, 6, 9, 12 months.):
Objective Response Rate (ORR, consisting of iCR plus iPR; only the non-irradiated lesions are measured) according to iRECIST in Arm1.

4. Adverse Events (Time Frame - Time Frame: From week 1 up to week 52):
Number of patients with adverse events (AEs) assessed on CTCAE v.4.03

5. HAFA assessment (Time Frame - At day 1 of week 1 and week 2; at day 1 from week 4 up to week 18; at week 22 (EoT)):
Assessment of the formation of human anti-fusion protein antibodies (HAFA) against L19TNF.

Studien-Arme

  • Experimental: Arm1: DTIC + L19TNF
    Patients will receive Dacarbazine (DTIC) on Day 1 and L19TNF on Days 1, 3 and 5 every 21 days.
  • Active Comparator: Arm 2: DTIC
    Patients will receive Dacarbazine (DTIC) on Day 1 every 21-day cycle .

Geprüfte Regime

  • Dacarbazine (DTIC):
    Dacarbazine (DTIC), 1000 mg/m2 or 850 mg/m2 on Day 1 of every 21-day cycle (based on results and DSMB evaluation in the safety run-in part of the study)
  • onfekafusp alfa (L19TNF):
    L19TNF, 13 μg/kg, on Day 1, 3, and 5 of every 21-day cycle for a maximum of 6 induction cycles. Patients experiencing apparent or real benefit with minimal or acceptable toxicity from the first 6 cycles of treatment, can receive, at investigator's discretion, maintenance treatment of 13 μg/kg, on Day 1 every 21-day

Quelle: ClinicalTrials.gov


Das könnte Sie auch interessieren
EHA 2021
  • SCD: Häufigere und längere VOC-bedingte Krankenhausaufenthalte nach Vorgeschichte von VOC-Hospitalisierungen – Ergebnisse einer Beobachtungsstudie
  • Real-World-Daten des ERNEST-Registers untermauern Überlebensvorteil unter Ruxolitinib bei primärer und sekundärer Myelofibrose
  • I-WISh-Studie: Ärzte sehen TPO-RAs als beste Option, um anhaltende Remissionen bei ITP-Patienten zu erzielen
  • Phase-III-Studie REACH2 bei steroidrefraktärer akuter GvHD: Hohes Ansprechen auf Ruxolitinib auch nach Crossover
  • SCD: Neues digitales Schmerztagebuch zur tagesaktuellen Erfassung von VOCs wird in Beobachtungsstudie geprüft
  • Französische Real-World-Studie: Eltrombopag meist frühzeitig nach ITP-Diagnose im Rahmen eines Off-label-Use eingesetzt
  • Fortgeschrittene systemische Mastozytose: Französische Real-World-Studie bestätigt klinische Studiendaten zur Wirksamkeit von Midostaurin
  • CML-Management weitgehend leitliniengerecht, aber verbesserungsfähig – Ergebnisse einer Querschnittsbefragung bei britischen Hämatologen
  • Britische Real-World-Studie: Kardiovaskuläres Risikomanagement bei MPN-Patienten in der Primärversorgung nicht optimal
  • Myelofibrose: Früher Einsatz von Ruxolitinib unabhängig vom Ausmaß der Knochenmarkfibrose